



**WHO Reference Reagent  
HEPATOCTE GROWTH FACTOR/SCATTER FACTOR  
NIBSC code: 96/564  
Instructions for use  
(Version 7.0, Dated 02/04/2013)**

### 1. INTENDED USE

This consists of a batch of ampoules (coded 96/564) containing CHO cell-derived heterodimeric hepatocyte growth factor/scatter factor (HGF/SF) analysed by international collaborative study and established as the First International Standard for Hepatocyte Growth Factor/Scatter Factor by the Expert Committee on Biological Standardization of the World Health Organisation. The material is intended to serve as a standard for the bioassay or immunoassay of human heterodimeric HGF/SF preparations. For assays of single-chain HGF/SF precursor, the corresponding standard, 96/556, should be used.

### 2. CAUTION

**This preparation is not for administration to humans or animals in the human food chain.**

The material is not of human or bovine origin. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory's safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

### 3. UNITAGE

The preparation in ampoules coded 96/564 is assigned a potency of 4000 International Units (IU) per ampoule. On the basis of the immunoassay results, preparation 96/564 is assigned a nominal mass content of 4 micrograms per ampoule. The bioactivity units and the immunoactivity units should not be assumed to be interconvertible.

### 4. CONTENTS

Country of origin of biological material: United Kingdom.  
Each ampoule contains the residue after freeze-drying of 1ml of a solution that contained:

4.5mg NaCl	3.0mg arginine
4.0mg Na phosphate pH 6.99	0.1mg Tween 20
30.0mg trehalose	rec HGF/SF

### 5. STORAGE

The ampoules are shipped at ambient temperature. Unopened ampoules should be stored at -20 degrees C in the dark. Freezing and reuse of reconstituted material should be avoided unless this can be validated for the particular laboratory, storage and assay conditions. Repeated freezing and thawing should be avoided. The ampoules do not contain bacteriostat and solutions of the ampouled material should not be assumed to be sterile.

**Please note: because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.**

### 6. DIRECTIONS FOR OPENING

DIN ampoules have an 'easy-open' coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

### 7. USE OF MATERIAL

**No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution**

For practical purposes each ampoule contains the same quantity of HGF/SF. The entire content of each ampoule should be completely dissolved in an accurately measured amount of buffer solution. The use of water to reconstitute ampoule contents is not recommended. It is recommended that, when possible, buffer containing carrier protein should be used to minimize loss by surface adsorption. The buffer should be compatible with the assay system used.

The material is intended to serve as a standard for the bioassay or immunoassay of human heterodimeric HGF/SF preparations but not for assay, particularly bioassay, of the single-chain form which may be variably converted to the mature, bioactive form during the bioassay procedure..

### 8. STABILITY

Reference materials are held at NIBSC within assured, temperature-controlled storage facilities and they should be stored on receipt as indicated on the label. Accelerated degradation studies have indicated that this material is suitably stable, when stored at -20°C or below, for the assigned values to remain valid until the material is withdrawn or replaced. These studies have also shown that the material is suitably stable for shipment at ambient temperature without any effect on the assigned values. Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact NIBSC.

### 9. REFERENCES

International Standards for hepatocyte growth factor/scatter factor: initial assessment of candidate materials and their evaluation by multicentre collaborative study.

Rafferty B, Maile P, Rigsby P, Gaines Das RE, Robinson CJ  
J Imm Meth (2001) 258:1-11

### 10. ACKNOWLEDGEMENTS

We gratefully acknowledge the contributions of the participants in the collaborative study. Preparations of rhHGF/SF for ampouling and for preliminary studies were generously provided to WHO by Mitsubishi Chemical Corporation, Yokohama 227, Japan; R&D systems Inc., Minneapolis, MN 55413, USA; and Dr E. Gherardi, University of Cambridge, MRC Centre, Cambridge, UK.

### 11. FURTHER INFORMATION

Further information can be obtained as follows;

This material: [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

WHO Biological Standards:

<http://www.who.int/biologicals/en/>

JCTLM Higher order reference materials:

<http://www.bipm.org/en/committees/jc/jctlm/>

Derivation of International Units:

[http://www.nibsc.org/standardisation/international\\_standards.aspx](http://www.nibsc.org/standardisation/international_standards.aspx)

Ordering standards from NIBSC:

<http://www.nibsc.org/products/ordering.aspx>

NIBSC Terms & Conditions:

[http://www.nibsc.org/terms\\_and\\_conditions.aspx](http://www.nibsc.org/terms_and_conditions.aspx)

### 12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to [enquiries@nibsc.org](mailto:enquiries@nibsc.org)

### 13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation's title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

#### 14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

Physical and Chemical properties	
Physical appearance: White lyophilised powder	Corrosive: No
Stable: No	Oxidising: No
Hygroscopic: Yes	Irritant: No
Flammable: No	Handling: See caution, Section 2
Other (specify):	
Toxicological properties	
Effects of inhalation:	Not established, avoid inhalation
Effects of ingestion:	Not established, avoid ingestion
Effects of skin absorption:	Not established, avoid contact with skin
Suggested First Aid	
Inhalation:	Seek medical advice
Ingestion:	Seek medical advice
Contact with eyes:	Wash with copious amounts of water. Seek medical advice
Contact with skin:	Wash thoroughly with water.
Action on Spillage and Method of Disposal	
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.	

establishment of international and other biological reference standards [http://www.who.int/bloodproducts/publications/TRS932Annex2\\_Inter\\_biol\\_efstandardsrev2004.pdf](http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biol_efstandardsrev2004.pdf) (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.

#### 15. LIABILITY AND LOSS

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC's Standard Terms and Conditions for the Supply of Materials (available at [http://www.nibsc.org/About\\_Us/Terms\\_and\\_Conditions.aspx](http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx) or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient's attention is drawn in particular to the provisions of clause 11 of the Conditions.

#### 16. INFORMATION FOR CUSTOMS USE ONLY

<b>Country of origin for customs purposes*:</b> United Kingdom * Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.
<b>Net weight:</b> 40mg
<b>Toxicity Statement:</b> Toxicity not assessed
<b>Veterinary certificate or other statement</b> if applicable.
<b>Attached:</b> No

#### 17. CERTIFICATE OF ANALYSIS

NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and